(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of -2.79% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Alkermes's revenue in 2025 is $1,513,770,000.On average, 8 Wall Street analysts forecast ALKS's revenue for 2025 to be $227,028,998,433, with the lowest ALKS revenue forecast at $224,687,565,087, and the highest ALKS revenue forecast at $231,191,601,570. On average, 8 Wall Street analysts forecast ALKS's revenue for 2026 to be $230,486,483,675, with the lowest ALKS revenue forecast at $217,357,208,265, and the highest ALKS revenue forecast at $250,485,051,915.
In 2027, ALKS is forecast to generate $228,252,401,066 in revenue, with the lowest revenue forecast at $220,068,350,292 and the highest revenue forecast at $247,022,124,930.